Pérez de José, AnaCarbayo, JavierPocurull, AnnaBada Bosch, TeresaCases Corona, Clara MariaShabaka, AmirRamos Terrada, NatàliaMartinez Valenzuela, LauraHuerta, AnaFernandez Lorente, LoretoMalek Marín, Tamara GelenGoicoechea, Marian2021-05-282021-05-282020-01-25https://hdl.handle.net/2445/177787Background: Direct-acting antiviral agents (DAAs) have shown high rates of sustained virological response in chronic hepatitis C virus (HCV) infection. However, the influence of DAAs on the course of kidney involvement in HCV-associated mixed cryoglobulinaemia (HCV-MC) has been little studied. The aim of this study was to analyse the effects of antiviral treatment on kidney prognosis and evolution in patients diagnosed with HCV-MC. Methods: The RENALCRYOGLOBULINEMIC study is an observational multicentre cohort study of 139 patients with HCV-MC from 14 Spanish centres. Clinical and laboratory parameters were measured before and after antiviral treatment. Primary endpoints were kidney survival and mortality after HCV-MC diagnosis. Secondary endpoints were clinical, immunological and virological responses after antiviral treatment. Results: Patients were divided into three groups based on the treatment received: treatment with DAAs (n = 100) treatment with interferon (IFN) and ribavirin (RBV) (n = 24) and no treatment (n = 15). Patients were followed up for a median duration of 138 months (interquartile range 70-251. DAA treatment reduced overall mortality {hazard ratio [HR] 0.12 [95% confidence interval (CI) 0.04-0.40]; P < 0.001} and improved kidney survival [HR 0.10 ( 95% CI 0.04-0.33); P < 0.001]. Conclusions: Results from the RENALCRYOGLOBULINEMIC study indicated that DAA treatment in patients with HCV-MC improves kidney survival and reduces mortality.application/pdfengcc by-nc (c) Pérez de José et al., 2021http://creativecommons.org/licenses/by-nc/3.0/es/Hepatitis CMalalties del ronyóHepatitis CKidney diseasesinfo:eu-repo/semantics/article2021-05-28info:eu-repo/semantics/openAccess33623683